GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, arexvy, influenza, and pandemic vaccines. It also provides medicine products for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. The company sells its products under the Anoro Ellipta, Nucala, Trelegy Ellipta, Ventolin, Xevudy, Keppra, Augmentin, Zejula, Blenrep, Jemperli, Ojjaara/Omjjara, Benlysta, Benlysta, Jesduvroq, Duvroq, Apretude, Cabenuva/Vocabria + Rekambys, Rukobia, Dovato, Juluca, Triumeq, Tivicay, Arexvy, Bexsero, Menveo, Synflorix, and Shingrix brand names. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.